Official Symbol: CEBPAprovided by HGNC
Official Full Name: CCAAT/enhancer binding protein (C/EBP), alphaprovided by HGNC
Primary Source: HGNC:1833
See related: HPRD:00296; MIM:116897
Gene type: protein coding
RefSeq status: REVIEWED
Organism: Homo sapiens
Lineage: Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo
Also known as: CEBP; C/EBP-alpha; CEBPA
Summary: The protein encoded by this intronless gene is a bZIP transcription factor which can bind as a homodimer to certain promoters and enhancers. It can also form heterodimers with the related proteins CEBP-beta and CEBP-gamma. The encoded protein has been shown to bind to the promoter and modulate the expression of the gene encoding leptin, a protein that plays an important role in body weight homeostasis. Also, the encoded protein can interact with CDK2 and CDK4, thereby inhibiting these kinases and causing growth arrest in cultured cells. [provided by RefSeq]

[Top][Help]Genomic regions, transcripts, and products

(minus strand) Go to reference sequence details Try our new Sequence Viewer

[Top][Help]Genomic context

chromosome: 19; Location: 19q13.1See CEBPA in MapViewer

[Top][Help]Bibliography

GeneRIFs: Gene References Into Function What's a GeneRIF?

	1.	Down-regulation of CEBPA activity contributes to MN1-modulated proliferation and impaired myeloid differentiation of hematopoietic cells.
	2.	Results suggest that the C/EBPalpha and C/EBPbeta transcription factors enhance expression of the TNFR1 protein in cells.
	3.	HCMV UL84 interacted with several regions of oriLyt that contain C/EBPalpha transcription factor binding sites.
	4.	These data suggest a mechanistic link between rs1230399 and bone mineral density through estrogen ERalpha/FOXA1 signaling pathways driven by long-distance enhancers.
	5.	This study stresses the differences in biological characteristics between CEBPAsingle-mut and CEBPAdouble-mut AML and their possible prognostic implication.
	6.	2 types of CEBPA mutations, N-terminal truncating mutations & in-frame bZip-domain mutations, were seen. They correlated with laboratory & clinical characteristics. CEBPA mutations are associated with lower relapse rate and improved survival.
	7.	CEBPA regulated the transcription of adiponectin gene via the distal enhancer and proximal region in its promoter.
	8.	relapse-free, disease-free, and overall survival were significantly longer in AML patients with the CEBPA mutation without an abnormal karyotype or associated FLT3-ITD.
	9.	In prostate cancer cells C/EBPalpha cannot function as a tumor suppressor
	10.	CEBPA mutations are associated with acute myelogenous leukemia.
	11.	In a multivariable analysis, only double -- but not single -- CEBPA mutations were identified as independent prognostic factors for survival in acute myeloid leukemia.
	12.	Patients with hapatocellular carcinoma and a markedly reduced C/EBP alpha expression had a significantly shorter survival with a hazard ratio of 5.45.
	13.	the N-terminal germline CEBPA mutation seems to promote the occurrence of an additional C-terminal mutation in CEBPA, which may represent the second genetic event in AML pathogenesis
	14.	Significant underlying heterogeneity within CEBPA mutation-positive acute myeloid leukemia with prognostic relevance.
	15.	a composite enhancer binding both PPARgamma and C/EBPa,b factors confers adipocyte-specific expression to Retn in mouse, and its absence from the human gene may explain the lack of adipocyte expression in humans.
	16.	Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)
	17.	because C/EBPalpha has been suggested as a potential tumor suppressor in breast cancer, these findings provide important mechanisms whereby 1,25(OH)(2)D(3) may act to inhibit growth of breast cancer cells
	18.	Bronchial smooth muscle cells of asthmatic patients have normal levels of CEBPA mRNA but inadequately reinitiate the translation into C/EBPalpha. Impaired translation control upstream of eIF4E might underlie the observed increased proliferation
	19.	CEBPA methylation is common in acute T cell leukemia but not acute myeloid leukemia
	20.	Aberrant methylation of the C/EBPalpha promoter region occurred in 10/80 diagnostic AML samples, and there was an inverse correlation between aberrant methylation of C/EBPalpha and the negative cell cycle regulator p15.
	21.	AP2alpha suppresses C/EBPalpha promoter activity and protein expression in head and neck squamous cell carcinoma.
	22.	Adipose tissue C/EBPalpha regulates several genes in glucose and lipid metabolism
	23.	aberrant silencing, as well as, inappropriate cytoplasmic localization of C/EBPalpha causes dysregulation of its function, suggesting that C/EBPalpha is a novel candidate tumor suppressor gene in pancreatic cancer cells
	24.	Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	25.	Hybrids of the bHLH and bZIP protein motifs display different DNA-binding activities in vivo vs. in vitro.
	26.	NRAMP1 proximal region binds CCAAT enhancer binding proteins alpha or beta and is crucial for transcription
	27.	Data strongly indicate that germline CEBPA mutations predispose to acute myeloid leukemia and that additional somatic CEBPA mutations contribute to the development of the disease.
	28.	Data show that the CEBPA mutation K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia.
	29.	Report the prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features.
	30.	ectopic expression of C/EBPepsilon, as well as C/EBPalpha, can induce the monocytic differentiation of myelomonocytic leukemic cells with MLL-fusion gene through the downregulation of Myc
	31.	CEBPA polymorphisms occurred more frequently than CEBPA mutations and could be identified across all prognostic risk groups
	32.	In malignant prostate C/EBPalpha may be available to regulate androgen receptor signaling through transient changes in its sub-cellular localization
	33.	Transcription of the invasion suppressor, CRMP-1, is reciprocally regulated at the promoter region by C/EBPalpha and Sp1.
	34.	four types of polymorphisms and 25 mutations were detected in CEBPA in samples from 390 patients with myelodysplastic syndrome (MDS) and hematologic malignancies
	35.	Low CEBPA levels were associated with leukopenia
	36.	Observational study of genetic testing. (HuGE Navigator)
	37.	Epigenetic alterations of C/EBP alpha are a frequent event in acute myeloid leukemia.
	38.	review of roles of cebpa and tip60 in genetics of leukemiogenesis
	39.	C/EBPalpha regulates FAT/CD36 gene expression at the transcriptional level.
	40.	These data show that apoptotic and growth inhibitory activities of C/EBPalpha are differentially regulated in different cells and that cooperation of cyclin D3 and C/EBPalpha is required for the inhibition of proliferation.
	41.	Based on our observations in the present study, we conclude that S248A mutation of C/EBPalpha leads to a reduction of granulocytic differentiation markers and a block in differentiation at the morphological level.
	42.	The effect of cell density and inflammatory conditions on the expression, compartmentalization, activation, and the anti-proliferative function of the GR in primary human lung fibroblast cultures, was studied.
	43.	CCAAT/enhancer-binding protein alpha antagonizes transcriptional activity of hypoxia-inducible factor 1 alpha with direct protein-protein interaction
	44.	In a cohort of 305 patients with de novo acute myeloid leukemia (excluding APL), the 6 bp insertion in the TAD2 domain did not have prognostic significance. It was also seen in some healthy controls.
	45.	Observational study of genotype prevalence. (HuGE Navigator)
	46.	Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)
	47.	Observational study of gene-disease association. (HuGE Navigator)
	48.	role of C/EBPalpha in the induction of the IGnTC gene as well as in I antigen expression
	49.	C/EBPalpha elicits a role as an effector downstream to HIF-1alpha in myeloid leukemic cells differentiation.
	50.	Acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.
	51.	Ubc9 is an important C/EBPalphap30 target through which C/EBPalphap30 enhances the sumoylation of C/EBPalphap42 to inhibit granulocytic differentiation.
	52.	C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage.
	53.	homozygous CEBPA mutations in acute myeloid leukemia may be due to segmental uniparental disomy
	54.	Inhibition of C/EBPalpha function may be causatively related to the leukemogenic potential of RUNX1/EVI1 chimeric transcription factor.
	55.	Activation of the CCAAT/enhancer binding protein alpha promoter was mediated by PI3 kinase.
	56.	Max as a novel co-activator of C/EBPalpha functions, thereby suggesting a possible link between C/EBPalpha and Myc-Max-Mad network.
	57.	Low C/EBPalpha is associated with myelopoiesis
	58.	diacylglycerol acyltransferase 2 expression is regulated by CAAT/enhancer-binding protein beta (C/EBPbeta) and C/EBPalpha during adipogenesis
	59.	ATF4 may regulate myeloid gene expression differentially by potentiating C/EBPepsilon but inhibiting C/EBPalpha-mediated transcriptional activation.
	60.	C/EBPalpha has a role in neutrophil differentiation
	61.	Novel protein kinase C isoforms regulate human keratinocyte differentiation by activating a p38 delta mitogen-activated protein kinase cascade that targets this protein
	62.	CEBPA mutation is apparently the primary event in the development of AML in this family.
	63.	Alterations in C/CAAT enhancer binding protein alpha and neuronal apoptosis inhibitory protein expression occurred in human adipose stromal-vascular cells after weight loss
	64.	C-EBP has an essential role in regulating PDGFRalpha expression
	65.	The emergence of a mutation in this protein is involved in the clonal evolution of myelodysplastic syndromes towards secondary acute myeloid leukemia.
	66.	affects on JunB expression and monocyte differentiation
	67.	C/EBP alpha binds to the lactoferrin promoter in nonexpressing cells.
	68.	interacts with Epstein-Barar virus ZTA protein through oligomerization and transactivates ZTA promoter by binding ZII and ZIIIB motifs during lytic cycle induction
	69.	Conditional expression of C/EBP alpha induced the C/EBP family members C/EBP beta and C/EBP epsilon and subsequent granulocyte differentiation.
	70.	Results suggest that reduced expression of C/EBPalpha may play a role in the development and/or progression of breast cancer.
	71.	Mutant CEBPA predicts favorable prognosis and may improve risk stratification in acute myeloid leukemia patients with normal cytogenetics.
	72.	Conserved amino acids regulate phosphoenolpyruvate carboxykinase (PEPCK) gene expression.
	73.	5'-region from -252 to -175, containing a consensus site for CCAAT/enhancer binding proteins alpha,beta (C/EBPalpha,beta), was essential for SAA1 induction in HASMCs.
	74.	phosphorylation induces conformational changes in C/EBP alpha, increasing the distance between the amino termini of C/EBPalpha dimers. This favors monocyte differentiation by blocking granulopoiesis.
	75.	CCAAT/enhancer-binding protein alpha (C/EBPalpha) activates transcription of the human microsomal epoxide hydrolase gene (EPHX1) through the interaction with DNA-bound NF-Y
	76.	CEBPA is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes.
	77.	The inhibition of HL-60/FAK differentiation resulted from both the induction of pRb hyperphosphorylation and the inhibition of association of pRb and c/EBPalpha.
	78.	Data show that human granulocytic differentiation is controlled by a regulatory circuitry involving miR-223 and two transcriptional factors, NFI-A and C/EBPalpha.
	79.	C/EBPalpha is essential for p21-mediated inhibition of G1 to S-phase progression by RAP in KSHV-infected host cells
	80.	Mutation of CEBPA is a recurrent finding in acute myeloid leukemia FAB type M1 and M2 and appears specific to the intermediate cytogenetic risk group patients.
	81.	Expression of mutated CEBPA in human CD34+ cord blood cells dramatically inhibited differentiation of both myeloid and erythroid lineages.
	82.	Phosphorylation-dependent switch of biological functions of C/EBPalpha promotes liver proliferation.
	83.	C/EBPalpha and PU.1 interact physically and colocalize in myeloid cells, and C/EBPalpha blocks the function of PU.1.
	84.	favorable prognostic significance of mutations in patients with de novo acute myeloid leukemia
	85.	role in mediating GADD153 expression is involved in deoxycholic acid-induced apoptosis
	86.	CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus lytic cycle reactivation
	87.	there is a physical interaction between the GABPalpha subunit and C/EBPalpha
	88.	CA150 is a co-repressor of C/EBP proteins and provides a possible mechanism for how C/EBPalpha can repress transcription of specific genes
	89.	CEBPA is activated by juxtaposition to the immunoglobulin gene enhancer upon its rearrangement with the immunoglobulin heavy-chain locus in precursor B-cell acute lymphoblastic leukemia harboring t(14;19)(q32;q13).
	90.	C/EBP alpha may play role in the regulation of the resistin gene expression
	91.	Expression levels of both C/EBPalpha isoforms in breast tumors were correlated with clinicopathological tumor parameters, expression of estrogen and progesterone receptors (ER, PR), Ki67 immunostaining, and expression of 7 cell-cycle regulatory proteins.
	92.	selective inhibition of G-CSF receptor expression by C/EBPalphap30-ER is due in part to its variable affinity for C/EBP sites
	93.	the level of basal as well as cAMP-stimulated IL-10 transcription depends on the expression of C/EBP alpha and beta and their binding to three motifs in the promoter/enhancer region
	94.	Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins.
	95.	Surfactant protein D gene regulation. Interactions among the conserved CCAAT/enhancer-binding protein elements.
	96.	C/EBPbeta enhancer, prolactin, significantly induced extracellular superoxide dismutase mRNA and protein.
	97.	Activation by C/EBP alpha and beta did not depend on their binding to the C/EBP site, since they still activated IGFBP-5 promoter.
	98.	C/EBP-alpha has been identified as a major activator of the human myeloid IgA Fc receptor promoter.
	99.	C/EBPalpha is a key transcription factor for full activation of human adiponectin gene transcription in mature adipocytes through interaction with response elements in the intronic enhancer.
	100.	CCAAT/enhancer-binding protein alpha has a synergy control motif that inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3
	101.	The intimate association of Pit-1 and C/EBPalpha at certain sites within the living cell nucleus could foster their combinatorial activities in the regulation of pituitary-specific gene expression.
	102.	C/EBP and RUNX/AML factors compete for binding to their respective cognate elements and bind to the CD11a promoter MS7 sequence in a cell lineage- and differentiation-dependent manner.
	103.	Findings implicate the CEBPA mutation as a potential marker for monitoring minimal residue disease.
	104.	CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid and show antitumor activity
	105.	C/EBPalpha protein half-life leading to its enhanced transactivation and DNA-binding capacity is prolonged by JNK1
	106.	These results indicate that C/EBPalpha regulates AFP gene expression through direct binding to multiple sites in the human AFP gene in cultured human cells.
	107.	HNF4alpha, CREM, HNF1alpha, and C/EBPalpha have roles in transcriptional regulation of the glucose-6-phosphatase gene by cAMP/vasoactive intestinal peptide in the intestine
	108.	expression level of the C/EBPalpha gene in hepatocytes was downregulated in response to proliferation signals
	109.	The HP196-197 insertion is not a mutation but a polymorphism and does not appear related to acute myeloid leukemia.
	110.	one of the major roles of Stat3 in the G-CSF signaling pathway is to augment the function of C/EBPalpha, which is essential for myeloid differentiation
	111.	CEBPA and CEBPe repress the leukemic phenotype of acute myeloid leukemia, suppress cell growth, and induce partial differentiation.
	112.	The CCAAT/enhancer-binding protein-alpha (CEBPA) is a transcription factor strongly implicated in myelopoiesis through control of proliferation and differentiation of myeloid progenitors.
	113.	The CCAAT-Enhancer-Binding Protein-alpha is involved in granulocytic differentiation of common myeloid progenitors.
	114.	a novel mechanism for IL-6-mediated repression of gene transcription that involves a reduction in C/EBPalpha-mediated activation
	115.	down-modulation of C/EBPalpha is a prerequisite for STAT5-induced effects on self-renewal and myelopoiesis in human cord blood-derived stem/progenitor cells
	116.	Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248.
	117.	may function as a tumor suppressor that is mutated during tumorigenesis. Abnormalties in C/EBPalpha function contribute to the development of malignancies in a variety of tisues.
	118.	C/EBP alpha and HNF-3 gamma cooperatively regulate CYP3A4 expression in hepatic cells by a mechanism that probably involves chromatin remodeling.
	119.	We conclude that C/EBPalpha and C/EBPbeta contribute to the deregulated expression of Bcl-2 in t(14;18) lymphoma cells
	120.	several regions of the C/EBP alpha protein are involved in inhibition of proliferative pathways in granulopoiesis
	121.	modulation of CEBPA by calreticulin represents a novel mechanism involved in the differentiation block in CBFB-SMMHC AML.
	122.	C/EBP alpha activates the latent myeloid differentiation program of megakaryocyte/erythroid progenitors and common lymphoid progenitors in transgenic mice; its global activation affects multilineage homeostasis in vivo.
	123.	Down-regulation and antiproliferative role of C/EBPalpha in lung cancer.
	124.	DNA hypermethylation of the upstream C/EBPalpha promoter region, not the core promoter region as previously reported, is critical in the regulation of C/EBPalpha expression in human lung cancer.
	125.	CCAAT/enhancer binding proteins alpha and beta have roles in growth and differentiation of hepatoblastomas

Submit: New GeneRIF Correction

[Top][Help]Interactions

Description ..........
Product	Interactant	Other Gene	Complex	Source	Pubs

C/EBP alpha	NP_001789.2	CDK2		HPRD	PubMed

NP_004355.1	Activating transcription factor 2	ATF2		HPRD	PubMed

NP_004355.1	NP_000066.1	CDK4		HPRD	PubMed

NP_004355.1	NP_005183.2	CDKN3		HPRD	PubMed

NP_004355.1	CCAAT/Enhancer binding protein, beta	CEBPB		HPRD	PubMed

NP_004355.1	CCAAT/enhancer binding delta	CEBPD		HPRD	PubMed

NP_004355.1	NP_001895.1	CTNNB1		HPRD	PubMed

NP_004355.1	Transcription factor 1	HNF1A		HPRD	PubMed

NP_004355.1	MSX2	MSX2		HPRD	PubMed

NP_004355.1	NP_002458.1	MYC		HPRD	PubMed

NP_004355.1	NP_000167.1	NR3C1		HPRD	PubMed

NP_004355.1	NP_002904.3	RFC1		HPRD	PubMed

NP_004355.1	NP_003111.1	SPI1		HPRD	PubMed
C/EBP-alpha interacts with the lactoferrin promoter.
NP_004355.2	NC_000003.9	LTF		BIND	PubMed
ASC-2 interacts with C/EBP alpha.
NP_004355.2	NP_054790.2	NCOA6		BIND	PubMed
C/EBP-alpha interacts with PIAS1.
NP_004355.2	AAC36702.1	PIAS1		BIND	PubMed
Reconstituted Complex
BioGRID:107479	BioGRID:106862	AR		BioGRID	PubMed
Two-hybrid
BioGRID:107479	BioGRID:107776	ATF2		BioGRID	PubMed
Co-purification; Far Western; Reconstituted Complex
BioGRID:107479	BioGRID:249547	Atf2		BioGRID	PubMed
Affinity Capture-Western; Co-fractionation; Reconstituted Complex
BioGRID:107479	BioGRID:107452	CDK2		BioGRID	PubMed
Affinity Capture-Western; Co-fractionation; Reconstituted Complex
BioGRID:107479	BioGRID:107454	CDK4		BioGRID	PubMed
Reconstituted Complex
BioGRID:107479	BioGRID:107480	CEBPB		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107479	BioGRID:107880	CTNNB1		BioGRID	PubMed
Reconstituted Complex
BioGRID:107479	BioGRID:108403	ESR1		BioGRID	PubMed
Reconstituted Complex
BioGRID:107479	BioGRID:110594	MSX2		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107479	BioGRID:110694	MYC		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107479	BioGRID:116691	NCOA6		BioGRID	PubMed
Reconstituted Complex
BioGRID:107479	BioGRID:109165	NR3C1		BioGRID	PubMed
Reconstituted Complex
BioGRID:107479	BioGRID:111850	RARB		BioGRID	PubMed
Reconstituted Complex
BioGRID:107479	BioGRID:110263	SMAD3		BioGRID	PubMed
Reconstituted Complex
BioGRID:107479	BioGRID:110264	SMAD4		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107479	BioGRID:112566	SPI1		BioGRID	PubMed

[Top][Help]General gene information

Markers

NoName(e-PCR): Links: UniSTS:485918

A002S24(e-PCR): Links: UniSTS:35898

CEBPA_537(e-PCR): Links: UniSTS:277093

SHGC-35476(e-PCR): Links: UniSTS:15241

RH64933(e-PCR): Links: UniSTS:6031

NoName(e-PCR): Links: UniSTS:481683

Cebpa(e-PCR), detects polymorphism: Links: UniSTS:516500

WI-16546(e-PCR): Links: UniSTS:45508

STS-T52003(e-PCR): Links: UniSTS:70876

STS-X87248(e-PCR): Links: UniSTS:34799

Phenotypes

Leukemia, acute myeloid: MIM: 601626

Genotypes

See CEBPA SNP Genotype Report

See CEBPA SNP Geneview Report

See CEBPA SNP Variation Viewer Report

Homology

Homologs of the CEBPA gene The CEBPA gene is conserved in cow, mouse, rat, chicken, and zebrafish.

Map Viewer (Mouse, Rat)

Pathways

KEGG pathway: Acute myeloid leukemia: 05221
KEGG pathway: Pathways in cancer: 05200

Gene Ontology Provided by GOA

Function	Evidence
RNA polymerase II transcription factor activity, enhancer binding	NAS	PubMed
protein dimerization activity	IEA
sequence-specific DNA binding	IEA
transcription factor binding	IPI	PubMed

Process	Evidence
cytokine-mediated signaling pathway	NAS	PubMed
generation of precursor metabolites and energy	TAS	PubMed
interspecies interaction between organisms	IEA
myeloid cell differentiation	NAS	PubMed
regulation of transcription, DNA-dependent	IEA
transcription from RNA polymerase II promoter	TAS	PubMed

Component	Evidence
nucleus	NAS	PubMed

[Top][Help]General protein information

Preferred Names: CCAAT/enhancer binding protein alpha

Names: CCAAT/enhancer binding protein alpha

[Top][Help]NCBI Reference Sequences (RefSeq)

RefSeqs maintained independently of Annotated Genomes

These reference sequences exist independently of genome builds. Explain

Genomic

NG_012022.1 RefSeqGene

Range

5000..7590

Download

GenBank FASTA Sequence Viewer (Graphics)

mRNA and Protein(s)

NM_004364.3 → NP_004355.2 CCAAT/enhancer binding protein alpha

Source sequence(s)

AC008738,BC027902

UniProtKB/Swiss-Prot

P49715

Conserved Domains (3) summary

cl02576
Location:281 – 334
Blast Score: 158

bZIP_1; bZIP transcription factor

cl02576
Location:281 – 334
Blast Score: 158

bZIP_1; bZIP transcription factor

cl02576
Location:281 – 334
Blast Score: 158

bZIP_1; bZIP transcription factor

RefSeqs of Annotated Genomes: Build 37.1

The following sections contain reference sequences that belong to a specific genome build. Explain

Genome Reference Consortium Human Build 37 (GRCh37), Primary_Assembly

Genomic

NC_000019.9

Range

33790935..33793319, complement

Download

GenBank FASTA Sequence Viewer (Graphics)
NT_011109.16

Range

6059153..6061537, complement

Download

GenBank FASTA Sequence Viewer (Graphics)

Alternate assembly (Celera)

Genomic

AC_000062.1

Range

30484500..30486884, complement

Download

GenBank FASTA Sequence Viewer (Graphics)
NW_927206.1

Range

6056068..6058452, complement

Download

GenBank FASTA Sequence Viewer (Graphics)

Alternate assembly (HuRef)

Genomic

AC_000151.1

Range

30291772..30294143

Download

GenBank FASTA Sequence Viewer (Graphics)
NW_001838492.2

Range

155918..158289

Download

GenBank FASTA Sequence Viewer (Graphics)

[Top][Help]Related Sequences

Nucleotide		Protein
genomic	AC008738.7 (169147..171531)	None
genomic	EU048234.1	ABS82765.1
genomic	U34070.1	AAC50235.1
mRNA	BC027902.1	AAH27902.1
mRNA	BC063874.1	AAH63874.1
mRNA	X87248.1	CAA60698.1
mRNA	Y11525.1	CAA72289.1
other-genetic	BC160133.1	AAI60133.1